CAS NO: | 98-92-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
50 g | 电议 |
生物活性 | Nicotinamide is a form of vitamin B3 or niacin that inhibitssirtuin2 (SIRT2) activityin vitro, with anEC50of 2 μM. Nicotinamide inhibits up to 90% melanoma cell number and increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibts tumor growthin vivoand improves survival of melanoma-bearing mice, which can be used for the research of skin cancers such as melanoma[1]. | ||||||||||||||||
IC50& Target[4] |
| ||||||||||||||||
体外研究 (In Vitro) | Nicotinamide (0-50 mM, 24/48 h ) reduces cell number in a time-dependent and dose-dependent manner in A375 and SK-MEL-28 cells[1].Nicotinamide (10-50 mM, 24 h ) makes A375 cells undergo accumulation in G1 phase, reduction in S phase, and increase inthe sub-G1 (apoptosis) phase[1].Nicotinamide (1-50 mM, 6 h ) increases NAD+, ATP and ROS levels in A375 and SK-MEL-28 cells[1].Nicotinamide (0.01-20 mM, 1 h) inhibits purified SIRT2 enzymatic activity in vitro with an EC50of 2 μM[1]. Cell Viability Assay[1]
Cell Cycle Analysis[1]
| ||||||||||||||||
体内研究 (In Vivo) | Nicotinamide (Intraperitoneal injection, 1500 and 1800 mg/Kg, 5 days per week) inhibits tumor growth in murine metastatic melanoma model[1].Nicotinamide (Intraperitoneal injection, 1800 mg/Kg, once a day, murine metastatic melanoma model) affects IFN-γ (a key mediator of cell-mediated anti-tumor immunity), increases the plasma levels of eotaxin and IL-5, reduces the plasma levels of IL-3, IL-12, RANTES and IL-10[1].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 122.12 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C6H6N2O | ||||||||||||||||
CAS 号 | 98-92-0 | ||||||||||||||||
中文名称 | 烟酰胺 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(409.43 mM;Need ultrasonic) H2O : ≥ 50 mg/mL(409.43 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|